Business Context and Reporting Period
This Form 10-Q is a quarterly report for Bioanalytical Systems, Inc. (Note: The request metadata lists "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc.) for the period ended March 31, 1999. The company manufactures scientific instruments for trace organic compound determination and provides laboratory services, consulting, and research. The fiscal year ends September 30.
Key Financial Metrics
| Metric | Six Months Ended Mar 31, 1999 | Six Months Ended Mar 31, 1998 |
|---|---|---|
| Total Revenue | $9,655,000 | $8,780,000 |
| Gross Profit | $4,633,000 | $5,034,000 |
| Operating Income | $358,000 | $652,000 |
| Net Income | $194,000 | $427,000 |
| Cash and Cash Equivalents (End of Period) | $854,000 | $2,985,000 |
| Total Debt (Current + Long-term) | $3,651,000 | $1,432,000 |
| Net Cash Used in Operating Activities | $(287,000) | $740,000 |
Revenue Mix (Six Months 1999): Product revenue was $4,624,000; Services revenue was $5,031,000.
Debt Structure: The company has a $3.5 million line of credit with $2,350,000 outstanding and an additional unused $4.0 million line of credit. Interest rates are tied to the prime rate (7.75% as of March 31, 1999).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 10.0% year-over-year for the six-month period, driven primarily by a 53.4% increase in services revenue ($5.0M vs $3.3M). This was offset by a 16.2% decline in product revenue ($4.6M vs $5.5M), attributed to reduced sales in Asia due to currency fluctuations.
- Profitability Decline: Net income decreased 54.6% to $194,000. Operating income dropped 45.1% to $358,000. Gross profit margin declined as cost of revenue increased 34.0% to $5.0M, largely due to the acquisition of a UK services unit in July 1998.
- Cash Flow Reversal: Operating cash flow turned negative, using $287,000 compared to providing $740,000 in the prior year. This was driven by a significant decrease in accounts payable and increased capital expenditures ($2.3M vs $1.4M).
- Liquidity: Cash balances decreased from $1.2M at the start of the period to $854,000 at period end. The company increased borrowings on its line of credit by $2.35M to fund operations and capital projects.
Outlook, Risks, and Management Commentary
- Capital Expenditures: The company anticipates decreased capital expenditures for the remainder of fiscal 1999 following significant spending on facility construction and laboratory equipment. Management expects cash from operations and existing credit lines to be sufficient for future requirements.
- Year 2000 (Y2K) Compliance: Management expects Y2K remediation to be substantially complete by summer 1999. Estimated capital expenditures for this project are less than $75,000. The company is assessing risks related to suppliers and customers failing to remediate their systems.
- Legal Proceedings: CMA Microdialysis Holding A.B. has sued the company alleging patent infringement regarding microdialysis probes. The company denies infringement and asserts the patent is invalid. Sales of the affected product represent less than 1% of revenue. Management believes the outcome will not be materially adverse, though legal expenses may impact earnings.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks to strategic plans, profitability, and growth strategies.
Investor Verification Checklist
- Debt Utilization: Verify the sustainability of the $2.35M draw on the $3.5M line of credit and the impact of interest rate fluctuations on future earnings.
- Operating Cash Flow: Investigate the drivers behind the shift from positive to negative operating cash flow, specifically the reduction in accounts payable and working capital changes.
- Product Revenue Trends: Assess the long-term impact of Asian currency devaluation on product sales and whether the shift toward services revenue is a sustainable strategic pivot.
- Legal Exposure: Monitor the status of the CMA Microdialysis patent litigation and associated legal costs.
- Y2K Costs: Confirm that actual Y2K remediation costs remain within the estimated $75,000 cap and do not escalate due to third-party failures.